Data on Tesomet as Capsule Given to FDA, May Allow Trial in PWS Patients

Data on Tesomet as Capsule Given to FDA, May Allow Trial in PWS Patients

309887

Data on Tesomet as Capsule Given to FDA, May Allow Trial in PWS Patients

Saniona announced that information requested by the U.S. Food and Drug Administration (FDA) to allow a new trial of Tesomet, a potential treatment for Prader-Willi syndrome (PWS), in a capsule form has been given to the agency. The company expects these details of the capsule’s manufacturing — requested by the FDA in April — will lead to Phase 2b trials opening in PWS and in hypothalamic obesity patients before year’s end, it said in a press…

You must be logged in to read/download the full post.